Free Trial
NASDAQ:INBX

Inhibrx Biosciences (INBX) Stock Price, News & Analysis

Inhibrx Biosciences logo
$18.35 +2.02 (+12.37%)
Closing price 04:00 PM Eastern
Extended Trading
$18.34 -0.01 (-0.03%)
As of 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Inhibrx Biosciences Stock (NASDAQ:INBX)

Key Stats

Today's Range
$15.83
$18.44
50-Day Range
$10.84
$16.29
52-Week Range
$10.80
$18.41
Volume
280,697 shs
Average Volume
96,094 shs
Market Capitalization
$265.71 million
P/E Ratio
0.16
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Inhibrx Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
20th Percentile Overall Score

INBX MarketRank™: 

Inhibrx Biosciences scored higher than 20% of companies evaluated by MarketBeat, and ranked 837th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Inhibrx Biosciences are expected to decrease in the coming year, from $104.88 to ($12.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Inhibrx Biosciences is 0.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.72.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Inhibrx Biosciences is 0.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.33.

  • Price to Book Value per Share Ratio

    Inhibrx Biosciences has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Inhibrx Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    7.93% of the float of Inhibrx Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Inhibrx Biosciences has a short interest ratio ("days to cover") of 7.5.
  • Change versus previous month

    Short interest in Inhibrx Biosciences has recently increased by 10.68%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Inhibrx Biosciences does not currently pay a dividend.

  • Dividend Growth

    Inhibrx Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.93% of the float of Inhibrx Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Inhibrx Biosciences has a short interest ratio ("days to cover") of 7.5.
  • Change versus previous month

    Short interest in Inhibrx Biosciences has recently increased by 10.68%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Inhibrx Biosciences this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Inhibrx Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    82.46% of the stock of Inhibrx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Inhibrx Biosciences' insider trading history.
Receive INBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

INBX Stock News Headlines

Inhibrx Biosciences, Inc. (INBX) - Yahoo Finance
Banks aren’t ready for this altcoin—are you?
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.
Inhibrx Biosciences Inc (INBX) - Investing.com
See More Headlines

INBX Stock Analysis - Frequently Asked Questions

Inhibrx Biosciences' stock was trading at $15.40 at the beginning of the year. Since then, INBX shares have increased by 14.1% and is now trading at $17.57.

Inhibrx Biosciences, Inc. (NASDAQ:INBX) issued its quarterly earnings data on Wednesday, May, 14th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.55) by $0.25.

Inhibrx Biosciences (INBX) raised $102 million in an IPO on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager.

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibrx Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Shopify (SHOP), Zoom Communications (ZM), CrowdStrike (CRWD) and Moderna (MRNA).

Company Calendar

Last Earnings
5/14/2025
Today
7/07/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INBX
Fax
N/A
Employees
166
Year Founded
N/A

Profitability

Trailing P/E Ratio
0.15
Forward P/E Ratio
0.17
P/E Growth
N/A
Net Income
$1.69 billion
Pretax Margin
861,486.44%

Debt

Sales & Book Value

Annual Sales
$200 thousand
Cash Flow
$126.32 per share
Price / Cash Flow
0.14
Book Value
$9.23 per share
Price / Book
1.92

Miscellaneous

Free Float
N/A
Market Cap
$256.08 million
Optionable
Optionable
Beta
-0.04
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:INBX) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners